Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NEnKTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7CUW9KSzVyPUCuNFAxOjh5IN88US=> MXzTRW5ITVJ?
LC-2-ad MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPwRolKSzVyPUCuNFAxOzF5IN88US=> NEGxV4pUSU6JRWK=
RL95-2 NVfBfFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CxNmlEPTB;MD6wNFA3PjhizszN MV3TRW5ITVJ?
MZ1-PC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrKeG5[UUN3ME2wMlAxODd{OTFOwG0> Mlm3V2FPT0WU
TE-8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P5cWlEPTB;MD6wNFEyPyEQvF2= M1n1b3NCVkeHUh?=
SW954 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMECxNVkh|ryP NYPvPYFVW0GQR1XS
TE-11 NW[yVI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMECxNlMh|ryP MkPoV2FPT0WU
PSN1 M4DVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvDflhOUUN3ME2wMlAxOTNizszN MVvTRW5ITVJ?
MOLT-4 NV3Ob2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMECxOFkh|ryP MWXTRW5ITVJ?
697 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMECxOUDPxE1? MmP4V2FPT0WU
ETK-1 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;nTWM2OD1yLkCwNVUzKM7:TR?= M4e3UnNCVkeHUh?=
TE-10 M2XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fXR2lEPTB;MD6wNFE2PCEQvF2= MmruV2FPT0WU
HUTU-80 NXfuWIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITQUW5KSzVyPUCuNFAyPjhizszN M2XBe3NCVkeHUh?=
NTERA-S-cl-D1 M4DReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHXTHdKSzVyPUCuNFAzODlizszN M3L5ZXNCVkeHUh?=
MFH-ino MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnnUHhKSzVyPUCuNFAzPjhizszN NUXFNoh5W0GQR1XS
IA-LM NYTWZoFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLMR5JtUUN3ME2wMlAxOjhizszN Ml\mV2FPT0WU
MC116 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml25TWM2OD1yLkCwNlg6KM7:TR?= NETTcGdUSU6JRWK=
RKO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XDUGlEPTB;MD6wNFI6QCEQvF2= MYHTRW5ITVJ?
MRK-nu-1 NFKySlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMECyPVkh|ryP MmC4V2FPT0WU
VA-ES-BJ M4jJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETpXVhKSzVyPUCuNFA{KM7:TR?= NUHh[5BXW0GQR1XS
KALS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XU|BKSzVyPUCuNFA{ODhizszN MnXvV2FPT0WU
BB30-HNC M3i2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLSTWM2OD1yLkCwN|E1KM7:TR?= NX3DepB3W0GQR1XS
ACN NFLiSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLzeFJKSzVyPUCuNFA{OTZizszN M3XqW3NCVkeHUh?=
TE-9 M4PZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy1cJN6UUN3ME2wMlAxOzJ4IN88US=> NHPEXGFUSU6JRWK=
SIG-M5 M3e1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LHNmlEPTB;MD6wNFMzPyEQvF2= MoLiV2FPT0WU
no-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\oN29KSzVyPUCuNFA{PjJizszN NWDGfGprW0GQR1XS
EW-1 M1\qOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxcIlKSzVyPUCuNFA{PzFizszN NYjac|JpW0GQR1XS
SK-LMS-1 NFLINmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvwTWM2OD1yLkCwOFAyKM7:TR?= MWLTRW5ITVJ?
GT3TKB NH;iSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGze5BKSzVyPUCuNFA1OzRizszN MWjTRW5ITVJ?
ES4 M2PHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEC0OFkh|ryP MnjOV2FPT0WU
IMR-5 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;TRVdyUUN3ME2wMlAxPDVizszN NXXUXWhPW0GQR1XS
NCI-H1648 NHn5VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WyWWlEPTB;MD6wNFQ3QSEQvF2= NHO1ZZpUSU6JRWK=
MV-4-11 M3rOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLoTWM2OD1yLkCwOFc2KM7:TR?= NH;iWW1USU6JRWK=
SK-UT-1 NHXZNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmwTWM2OD1yLkCwOFgh|ryP M373S3NCVkeHUh?=
NB13 NWnSbGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILD[3BKSzVyPUCuNFA1QTFizszN MnfHV2FPT0WU
DJM-1 NYPU[pBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvTWM2OD1yLkCwOVMh|ryP NWPtbXdnW0GQR1XS
ES8 NEjoWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rEe2lEPTB;MD6wNFU{QCEQvF2= MWHTRW5ITVJ?
TE-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEC1O{DPxE1? NW\SbGhpW0GQR1XS
KS-1 NHv0UGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPjTWM2OD1yLkCwOVgzKM7:TR?= NXLMS442W0GQR1XS
TE-1 NUXXd2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEC2NFYh|ryP NWLp[ZptW0GQR1XS
ATN-1 NUfj[FVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEC2NFkh|ryP MXzTRW5ITVJ?
A4-Fuk NVvuTYRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;USXNKSzVyPUCuNFA3OTFizszN MXHTRW5ITVJ?
ALL-PO NVztb|BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEC2N{DPxE1? MV7TRW5ITVJ?
BE-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32zO2lEPTB;MD6wNFY{PiEQvF2= MUjTRW5ITVJ?
KM12 M{TYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjWeppKSzVyPUCuNFA3OzdizszN MmW1V2FPT0WU
NOS-1 M1m3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzCTWM2OD1yLkCwOlUh|ryP NIq0WG9USU6JRWK=
SW962 NVe5WZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL4TWM2OD1yLkCwOlYzKM7:TR?= MVHTRW5ITVJ?
OCUB-M NHPYXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jFTmlEPTB;MD6wNFY3OiEQvF2= M1fN[nNCVkeHUh?=
NCI-H510A MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrLVlNKSzVyPUCuNFA3PjVizszN NV34bXdPW0GQR1XS
EW-16 NHqyfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmTWM2OD1yLkCwOlk1KM7:TR?= NFvrZ|hUSU6JRWK=
KGN NHTwZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\rTWM2OD1yLkCwO|EzKM7:TR?= M3;MZ3NCVkeHUh?=
LS-411N NI\4Um5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;RTWM2OD1yLkCwO|E4KM7:TR?= MVTTRW5ITVJ?
Becker NH\PcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhNnFKSzVyPUCuNFA4OiEQvF2= M3noT3NCVkeHUh?=
HC-1 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\1TWM2OD1yLkCwO|IyKM7:TR?= Ml;IV2FPT0WU
CESS M3\6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEC3N|ch|ryP M2jNXXNCVkeHUh?=
KURAMOCHI NGnSbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5TWM2OD1yLkCwO|Q5KM7:TR?= MVHTRW5ITVJ?
TGBC24TKB MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrqTWM2OD1yLkCwO|UzKM7:TR?= NFHCfVBUSU6JRWK=
SW982 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInVc|hKSzVyPUCuNFA4PjZizszN M1LTOnNCVkeHUh?=
HCE-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEC3Olch|ryP M4rQSXNCVkeHUh?=
LOUCY NHXLO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzTcoJoUUN3ME2wMlAxPzd3IN88US=> NV7PTodtW0GQR1XS
8-MG-BA NV70bI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjWdZFxUUN3ME2wMlAxPzl4IN88US=> MWrTRW5ITVJ?
HT-144 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PacGlEPTB;MD6wNFgh|ryP NXPCWYhyW0GQR1XS
LXF-289 NXzhU2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEC4NVgh|ryP M3X2ZnNCVkeHUh?=
RS4-11 M{nrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M375OWlEPTB;MD6wNFg{PiEQvF2= MVjTRW5ITVJ?
DEL NGnmSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD0TWM2OD1yLkCwPFQ2KM7:TR?= M{DWOXNCVkeHUh?=
OCI-AML2 NU\lbYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\GTHI5UUN3ME2wMlAxQDV{IN88US=> MXXTRW5ITVJ?
CCRF-CEM NVz6N5FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvtWYZKSzVyPUCuNFA5PzFizszN MVvTRW5ITVJ?
A388 NVT0cmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHUTWM2OD1yLkCwPFc1KM7:TR?= Mkm3V2FPT0WU
KNS-42 M4rz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEC4PVEh|ryP NEDCeXFUSU6JRWK=
OVCAR-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnPTo1KSzVyPUCuNFA6ODRizszN NH72[3ZUSU6JRWK=
NCI-H1355 M{DVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEC5NVQh|ryP Ml;wV2FPT0WU
BL-70 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XadWlEPTB;MD6wNFk{KM7:TR?= MV7TRW5ITVJ?
BL-41 NUPER|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC5N|Qh|ryP MkL1V2FPT0WU
A101D M{LweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHnTWM2OD1yLkCwPVYh|ryP MVvTRW5ITVJ?
HL-60 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3U[GZKSzVyPUCuNFA6PjZizszN NGDQOW9USU6JRWK=
COR-L279 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfaVXNPUUN3ME2wMlAxQTl7IN88US=> MXTTRW5ITVJ?
NCI-SNU-16 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DT[2lEPTB;MD6wNVAxQCEQvF2= NXX3VnBUW0GQR1XS
Calu-6 M2qwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLDXoR4UUN3ME2wMlAyODF{IN88US=> Mly5V2FPT0WU
SR NIDxbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfhc5JKSzVyPUCuNFExOjZizszN MVfTRW5ITVJ?
QIMR-WIL M3SzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTOWXRXUUN3ME2wMlAyODN|IN88US=> MofVV2FPT0WU
LB647-SCLC MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr4TWM2OD1yLkCxNFUyKM7:TR?= MojzV2FPT0WU
RPMI-8226 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMcmlEPTB;MD6wNVExOiEQvF2= MlrtV2FPT0WU
SK-PN-DW NVPaS5l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW5TWM2OD1yLkCxNVEzKM7:TR?= M4PIUXNCVkeHUh?=
SF268 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEGxOVEh|ryP NFyzZZRUSU6JRWK=
HD-MY-Z NYDQcHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEGxOlMh|ryP M2jIfnNCVkeHUh?=
DOHH-2 M{\5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1yLkCxNlA{KM7:TR?= MmTXV2FPT0WU
SCC-3 NYfFNow1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2NmlEPTB;MD6wNVIxPCEQvF2= MnXaV2FPT0WU
ST486 NIfEOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj6eVBKSzVyPUCuNFEzODRizszN NYLxe|JrW0GQR1XS
NALM-6 NUTrbmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEGyNVQh|ryP MoWxV2FPT0WU
NCI-H1436 NVv5fngzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD1yLkCxNlMyKM7:TR?= NYrRPGFlW0GQR1XS
KE-37 NETGVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvdINPUUN3ME2wMlAyOjN2IN88US=> MVPTRW5ITVJ?
RPMI-8402 NVrERo1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\2[I9[UUN3ME2wMlAyOjV4IN88US=> NV25d5dSW0GQR1XS
RXF393 NXv1c2V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn6TWM2OD1yLkCxNlU4KM7:TR?= MYLTRW5ITVJ?
KARPAS-45 NVnK[5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnyOlRKUUN3ME2wMlAyOjdizszN M1rFRnNCVkeHUh?=
HOP-62 NUDzdmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDFV29UUUN3ME2wMlAyOjd4IN88US=> NVPOTYVbW0GQR1XS
ES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnNZnJEUUN3ME2wMlAyOjh6IN88US=> NVy0Xnd5W0GQR1XS
L-363 NVPFTJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PjbWlEPTB;MD6wNVM2OSEQvF2= MW\TRW5ITVJ?
GI-1 NULwWopqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n5O2lEPTB;MD6wNVM4OyEQvF2= NVq0d4xPW0GQR1XS
CTV-1 M4DwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEG0O|gh|ryP NG\ZcWVUSU6JRWK=
TE-5 NVPVd4xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y0RWlEPTB;MD6wNVQ6PiEQvF2= M37HcnNCVkeHUh?=
SNU-C2B MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rnOmlEPTB;MD6wNVQ6PiEQvF2= Mki3V2FPT0WU
K-562 M1G0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD1yLkCxOVE3KM7:TR?= M3v5NXNCVkeHUh?=
SNB75 M3LDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjhemNKSzVyPUCuNFE2PCEQvF2= NFj6dFBUSU6JRWK=
MOLT-13 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjjTWM2OD1yLkCxOlM4KM7:TR?= M4\XenNCVkeHUh?=
LS-123 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEG2OlQh|ryP MlP3V2FPT0WU
NCI-SNU-5 NVLldVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPKSFlpUUN3ME2wMlAyPzBzIN88US=> NInsW5pUSU6JRWK=
Daudi MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL3OWZzUUN3ME2wMlAyPzB6IN88US=> Mn\jV2FPT0WU
A253 NXi2dVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O3dWlEPTB;MD6wNVc{QCEQvF2= M33I[XNCVkeHUh?=
TGBC1TKB MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEG3OVIh|ryP MkntV2FPT0WU
SJSA-1 M3mzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLHTWM2OD1yLkCxO|Y4KM7:TR?= MYTTRW5ITVJ?
NCCIT NFnQVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HzeWlEPTB;MD6wNVc3QSEQvF2= MUjTRW5ITVJ?
NCI-H69 NYjYV3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEG3O|gh|ryP NWX3[W1oW0GQR1XS
SH-4 M1zIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEG4PVUh|ryP MmLuV2FPT0WU
HCC1187 NU\ZVIVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLLTWM2OD1yLkCxPVI1KM7:TR?= MUHTRW5ITVJ?
HCC1599 NHnQOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEKwNkDPxE1? NX[yZ4JDW0GQR1XS
ONS-76 NIDsXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjpbJpKSzVyPUCuNFIxOzZizszN Ml\0V2FPT0WU
KU812 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO2Z3lKSzVyPUCuNFIxOzlizszN MWjTRW5ITVJ?
ML-2 NWHsbINCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEKwOFch|ryP NH7OfXVUSU6JRWK=
HCE-T Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG3OYFKSzVyPUCuNFIxQTJizszN NXXyblJrW0GQR1XS
NCI-H446 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTDXnFKSzVyPUCuNFIyOTJizszN NFrrTGhUSU6JRWK=
RPMI-6666 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nzTmlEPTB;MD6wNlE1QSEQvF2= NYnwW255W0GQR1XS
MOLT-16 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGyTWM2OD1yLkCyNVU{KM7:TR?= MnnYV2FPT0WU
JiyoyeP-2003 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjBc2MyUUN3ME2wMlAzOTd4IN88US=> MVnTRW5ITVJ?
MHH-PREB-1 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\CN2lEPTB;MD6wNlE6OSEQvF2= MnP3V2FPT0WU
MC-CAR M2XkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET5eZRKSzVyPUCuNFI{OjZizszN NEHyNYNUSU6JRWK=
BC-3 NWDy[INDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm1[JZKSzVyPUCuNFI{PDRizszN MU\TRW5ITVJ?
KINGS-1 M13WW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD1yLkCyN|U2KM7:TR?= MXzTRW5ITVJ?
PF-382 NUXHOVczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLMTWM2OD1yLkCyN|c5KM7:TR?= M{\aOnNCVkeHUh?=
J-RT3-T3-5 NV;jTY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEKzPFMh|ryP NF\jVIlUSU6JRWK=
SF539 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kVmJKSzVyPUCuNFI1ODFizszN MXTTRW5ITVJ?
LB831-BLC MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXOcIxUUUN3ME2wMlAzPDh3IN88US=> NGHKVoZUSU6JRWK=
DMS-114 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzMUGRKSzVyPUCuNFI2ODJizszN NFfpVZpUSU6JRWK=
LB1047-RCC MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEK1NUDPxE1? M4O0NXNCVkeHUh?=
LB771-HNC M2DqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZTWM2OD1yLkCyOVM1KM7:TR?= NUTrdHlkW0GQR1XS
BB65-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEK1N|Qh|ryP M3\6OXNCVkeHUh?=
BV-173 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPxU2lyUUN3ME2wMlAzPTV2IN88US=> NETyTmlUSU6JRWK=
ARH-77 NH7QR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEK2NFEh|ryP NXfYSYZmW0GQR1XS
IST-MEL1 NYPze3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrHUY4zUUN3ME2wMlAzPjJ|IN88US=> NIHPN|dUSU6JRWK=
NB1 M3HYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfFflRKSzVyPUCuNFI3QDdizszN MkfkV2FPT0WU
EoL-1-cell MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HPeWlEPTB;MD6wNlY5QCEQvF2= MnjBV2FPT0WU
KY821 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEK2PVch|ryP M3X4eXNCVkeHUh?=
CMK MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEK3N|Qh|ryP M{LsbXNCVkeHUh?=
NCI-H2126 NW\Nc5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmR2lEPTB;MD6wNlc3QCEQvF2= MUTTRW5ITVJ?
NCI-H526 M3rLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEK4PVEh|ryP MWjTRW5ITVJ?
COLO-684 NXjkXpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEK5NFgh|ryP Mo\zV2FPT0WU
NCI-H747 NYfqVZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPxNFBKSzVyPUCuNFI6OzNizszN MX7TRW5ITVJ?
JAR NIDwcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHN[2I3UUN3ME2wMlAzQTR4IN88US=> NFvabXhUSU6JRWK=
MEG-01 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TXcGlEPTB;MD6wNlk4QCEQvF2= M1THRnNCVkeHUh?=
MONO-MAC-6 NXO1W5lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fLemlEPTB;MD6wN|AzOyEQvF2= MYrTRW5ITVJ?
IST-SL1 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXUpczUUN3ME2wMlA{ODR{IN88US=> NVXSbnFIW0GQR1XS
CPC-N M3rNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD1yLkCzNFc6KM7:TR?= MV3TRW5ITVJ?
NCI-H1963 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEOxN|Eh|ryP MVTTRW5ITVJ?
K052 NVT1U29JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LfZY4UUN3ME2wMlA{OjR5IN88US=> MV7TRW5ITVJ?
KM-H2 M1H0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CzbWlEPTB;MD6wN|MxPyEQvF2= NICwSJNUSU6JRWK=
TE-12 NIraSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtTWM2OD1yLkCzN|A6KM7:TR?= MV7TRW5ITVJ?
TK10 M2fMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK4[5ZKSzVyPUCuNFM{PTZizszN MYPTRW5ITVJ?
NMC-G1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXpcVZIUUN3ME2wMlA{PDV{IN88US=> MljDV2FPT0WU
no-11 NH7MdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKzXYRGUUN3ME2wMlA{PDd6IN88US=> NYTPWHRYW0GQR1XS
NCI-H524 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEO1Nlkh|ryP MkLQV2FPT0WU
MHH-CALL-2 NHHENGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX1TWM2OD1yLkCzOVYzKM7:TR?= NWDHTYQyW0GQR1XS
GB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHrSZo2UUN3ME2wMlA{PiEQvF2= M32we3NCVkeHUh?=
OPM-2 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnNT49KSzVyPUCuNFM3PzNizszN M2XIcHNCVkeHUh?=
RH-1 M4fIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHRdoFJUUN3ME2wMlA{QDF7IN88US=> M3fLPHNCVkeHUh?=
NCI-H64 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nlbmlEPTB;MD6wN|g2PyEQvF2= MUHTRW5ITVJ?
EVSA-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLIWGFkUUN3ME2wMlA{QTJ|IN88US=> NHLXRXVUSU6JRWK=
KARPAS-299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEO5PEDPxE1? MWrTRW5ITVJ?
MZ7-mel MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP5XpNrUUN3ME2wMlA1ODRizszN MUTTRW5ITVJ?
LB373-MEL-D M3rEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXaO3RKSzVyPUCuNFQyODVizszN NVLueZEyW0GQR1XS
HEL NY\ZN5BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj1dZhKSzVyPUCuNFQyPCEQvF2= M{nL[3NCVkeHUh?=
SW872 NUf5fVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n6UmlEPTB;MD6wOFIyKM7:TR?= MXvTRW5ITVJ?
DU-4475 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoThTWM2OD1yLkC0NlQ1KM7:TR?= MnjYV2FPT0WU
IST-SL2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDWdpNpUUN3ME2wMlA1Ojd3IN88US=> MVfTRW5ITVJ?
NCI-H82 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMESzNFch|ryP M4ftfHNCVkeHUh?=
LC4-1 M{m5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqyOpNsUUN3ME2wMlA1OzVzIN88US=> MmTGV2FPT0WU
HDLM-2 M3nCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMESzPVIh|ryP MljqV2FPT0WU
MMAC-SF MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMES1N|Qh|ryP NYKxTWRUW0GQR1XS
L-540 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMES2N|kh|ryP M{nkTXNCVkeHUh?=
MZ2-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHmTWM2OD1yLkC0O|QzKM7:TR?= MX\TRW5ITVJ?
LU-134-A MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6yTWM2OD1yLkC0O|c{KM7:TR?= MWXTRW5ITVJ?
UACC-257 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XFPWlEPTB;MD6wOFg1QSEQvF2= NGXlc4pUSU6JRWK=
NCI-H1581 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe0R4lKSzVyPUCuNFQ6PTNizszN NWHLWZRTW0GQR1XS
NB17 M4LSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj5dFlKSzVyPUCuNFQ6PzlizszN NGfhfXFUSU6JRWK=
SBC-1 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fOTWlEPTB;MD6wOVA1OiEQvF2= MWnTRW5ITVJ?
TALL-1 NXXWUIlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O1VGlEPTB;MD6wOVA1PSEQvF2= MmDVV2FPT0WU
NCI-H1304 NEHFb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f6UmlEPTB;MD6wOVIxQCEQvF2= MXnTRW5ITVJ?
NEC8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvLSYNKSzVyPUCuNFUzQDZizszN MU\TRW5ITVJ?
CAL-148 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEW0N|kh|ryP NWrNWFlmW0GQR1XS
CGTH-W-1 NFjp[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXzTWM2OD1yLkC1OFQ6KM7:TR?= NF[1UYdUSU6JRWK=
NCI-H889 NHHJcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1UZVKSzVyPUCuNFU2QTJizszN MVXTRW5ITVJ?
GR-ST NITOWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0SndKSzVyPUCuNFU3OjFizszN MX3TRW5ITVJ?
KARPAS-422 NHjLZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rrUWlEPTB;MD6wOVY2KM7:TR?= M3vFSXNCVkeHUh?=
RPMI-8866 M2LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEW3NVIh|ryP NEXxOIxUSU6JRWK=
SCLC-21H Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M125V2lEPTB;MD6wOVg5PCEQvF2= Mnz3V2FPT0WU
COR-L88 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEW5Nlch|ryP MWrTRW5ITVJ?
LU-139 NIHhe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f3dWlEPTB;MD6wOVk5PiEQvF2= MlT2V2FPT0WU
SF126 NHvEOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL3TWM2OD1yLkC2NVM{KM7:TR?= M1XURXNCVkeHUh?=
NCI-H1882 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ReoRKSzVyPUCuNFY1OjRizszN NEHLVmJUSU6JRWK=
EW-24 NYjPeVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwME[0PFMh|ryP MVfTRW5ITVJ?
CP67-MEL M2jJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vjN2lEPTB;MD6wOlgyKM7:TR?= NF3rbm9USU6JRWK=
DG-75 M2K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3GdXpKUUN3ME2wMlA3QDl7IN88US=> Moj5V2FPT0WU
LOXIMVI MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjzdZhKSzVyPUCuNFcxOjhizszN MmPqV2FPT0WU
HH MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7sPWNTUUN3ME2wMlA4OTV5IN88US=> MYLTRW5ITVJ?
K5 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLSUYVxUUN3ME2wMlA4OjJ4IN88US=> NGPFTWlUSU6JRWK=
EC-GI-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEeyOVch|ryP M3;4SXNCVkeHUh?=
SK-N-DZ M4TsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInXWGNKSzVyPUCuNFc{ODdizszN M1H3dXNCVkeHUh?=
A3-KAW NYr5PYt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zxWGlEPTB;MD6wO|M2OSEQvF2= MVPTRW5ITVJ?
MLMA MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP2TWM2OD1yLkC3OFY2KM7:TR?= MUPTRW5ITVJ?
LB996-RCC NWHoOmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjINZpKSzVyPUCuNFc4ODdizszN MnzOV2FPT0WU
OS-RC-2 NXjoZ3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LhV2lEPTB;MD6wO|c1QCEQvF2= NV62Vlc5W0GQR1XS
CTB-1 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD1yLkC3PFEh|ryP NYr3OFJSW0GQR1XS
IST-MES1 NHXLV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPiTJJKSzVyPUCuNFc6OTJizszN NXjDTHQ{W0GQR1XS
LS-1034 NEHVcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jUfWlEPTB;MD6wPFA{PSEQvF2= M{Xu[3NCVkeHUh?=
HT NX7NS2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHFSoxDUUN3ME2wMlA5ODh4IN88US=> MWHTRW5ITVJ?
NCI-H2141 NGjPWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;BTWM2OD1yLkC4NUDPxE1? NFfEdIlUSU6JRWK=
LB2518-MEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3PTWM2OD1yLkC4NVQyKM7:TR?= MUDTRW5ITVJ?
GI-ME-N M1njdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXRS5N2UUN3ME2wMlA5PDV{IN88US=> Mmr0V2FPT0WU
TGW NGryWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUezZmVnUUN3ME2wMlA5PjB5IN88US=> MXPTRW5ITVJ?
SK-NEP-1 NU[3c3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn6WZFKSzVyPUCuNFg3PDFizszN M2jNW3NCVkeHUh?=
NOMO-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMEmyO|Uh|ryP NY\wNmZbW0GQR1XS
ES6 M1ewNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHaTWM2OD1yLkC5OVg6KM7:TR?= Ml\SV2FPT0WU
NCI-H209 NF3VVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i1N2lEPTB;MD6wPVc5PiEQvF2= NFPSfYJUSU6JRWK=
GAK M3zzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHETlZSUUN3ME2wMlExOTZizszN NWLkd5E{W0GQR1XS
BC-1 NXT1O5ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMUCzOlEh|ryP MnHMV2FPT0WU
KLE MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDFT2lKSzVyPUCuNVA1PDNizszN NYqy[phNW0GQR1XS
EW-3 M3rBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorrTWM2OD1yLkGwPVgh|ryP NVjSdnp{W0GQR1XS
NKM-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4cWlEPTB;MD6xNVEh|ryP NUTIOJlxW0GQR1XS
D-336MG M2jxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXPTWM2OD1yLkGxNlQ1KM7:TR?= MkPVV2FPT0WU
NB69 M2Tab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv3TWM2OD1yLkGxN|AyKM7:TR?= MnnJV2FPT0WU
D-263MG NGDOSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq2W3E3UUN3ME2wMlEyPzF{IN88US=> MnjhV2FPT0WU
KP-N-YS NF\LfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[zfo1KSzVyPUCuNVIzQTFizszN NYH4T4ZuW0GQR1XS
NCI-H1155 NIPENpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2dmlEPTB;MD6xNlU2QCEQvF2= MlK5V2FPT0WU
BOKU MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrXTHZEUUN3ME2wMlEzPTd7IN88US=> NHzEU4NUSU6JRWK=
LAMA-84 NX;wSmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z4cGlEPTB;MD6xNlk6KM7:TR?= Ml64V2FPT0WU
Raji M3LlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TYbWlEPTB;MD6xN|EyPyEQvF2= NX3Ec3A4W0GQR1XS
LU-65 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7BeZhmUUN3ME2wMlE{OzB5IN88US=> MVXTRW5ITVJ?
NCI-H187 NGfqNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rKR2lEPTB;MD6xN|kzPCEQvF2= NX;ad5BlW0GQR1XS
GCIY MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LVbmlEPTB;MD6xOFkxOSEQvF2= M4K1XnNCVkeHUh?=
NCI-H2107 M13LPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HQWGlEPTB;MD6xOVA5KM7:TR?= NEPEcZJUSU6JRWK=
NCI-H1522 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn72TWM2OD1yLkG1NlY3KM7:TR?= MYLTRW5ITVJ?
NB6 NUS0T3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG5bGNNUUN3ME2wMlE2PjJ|IN88US=> NEXScndUSU6JRWK=
EM-2 NYPkW5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjxRYlKSzVyPUCuNVU4ODZizszN MlvrV2FPT0WU
HCC2218 NE\GWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorkTWM2OD1yLkG1PVgh|ryP NGGzZ|JUSU6JRWK=
NCI-H748 NXzCRplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nBb2lEPTB;MD6xOlM4PiEQvF2= MoW1V2FPT0WU
MS-1 NF\lVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO4dIxKSzVyPUCuNVY2OzdizszN MmfKV2FPT0WU
NB5 M{XsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMU[1PVch|ryP NVLjXphXW0GQR1XS
OMC-1 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr5U|NZUUN3ME2wMlE3Pjh6IN88US=> MXTTRW5ITVJ?
NCI-H345 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PhfWlEPTB;MD6xOlkzQCEQvF2= NGnqfJJUSU6JRWK=
L-428 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki5TWM2OD1yLkG2PVQ2KM7:TR?= NH3CWG9USU6JRWK=
SCH MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjDVZNJUUN3ME2wMlE5Pjh3IN88US=> NGPvd4xUSU6JRWK=
NCI-H1417 M4jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnXb|JKSzVyPUCuNVkzOjdizszN NH7IN3hUSU6JRWK=
COLO-320-HSR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPkfG53UUN3ME2wMlE6PTN{IN88US=> NHLjTZFUSU6JRWK=
BT-474 NWLCSHVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TwPWlEPTB;MD6yNFg6OiEQvF2= MnzZV2FPT0WU
GDM-1 M1e3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMkG5O|Eh|ryP NYLifYlLW0GQR1XS
NCI-H2196 M1rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm3RlNKSzVyPUCuNlIzOzVizszN NInp[INUSU6JRWK=
KP-N-RT-BM-1 M2i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLzTWM2OD1yLkKyN|Q6KM7:TR?= M2fuOHNCVkeHUh?=
KNS-81-FD NF;NXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\rT2tkUUN3ME2wMlIzQTV6IN88US=> NHiycoVUSU6JRWK=
COLO-668 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BPJBKSzVyPUCuNlM3PzVizszN NVf4fWFNW0GQR1XS
C2BBe1 NYezUY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPIWmVjUUN3ME2wMlI3PzR5IN88US=> NF\oO5lUSU6JRWK=
Ramos-2G6-4C10 NITQSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnYdnBKSzVyPUCuNlY6PTRizszN MkHyV2FPT0WU
CAS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS4NGJKSzVyPUCuNlcxQTZizszN NWrCbodNW0GQR1XS
GOTO NVTMSXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[wSVNKSzVyPUCuNlc5QTRizszN MmqxV2FPT0WU
LP-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkiwOVch|ryP NWPicJREW0GQR1XS
NCI-SNU-1 NIjFSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6VoI2UUN3ME2wMlI6PDJ{IN88US=> NWf6flJVW0GQR1XS
EB-3 M3LBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\2fGlEPTB;MD6yPVk4QSEQvF2= MljQV2FPT0WU
MHH-NB-11 NELWdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX1Npk{UUN3ME2wMlMxPDB{IN88US=> M3[5Z3NCVkeHUh?=
SK-N-FI NIK3[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHwTWM2OD1yLkOxOlkzKM7:TR?= MmfFV2FPT0WU
HCC2157 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnBVoU{UUN3ME2wMlM{QTF|IN88US=> M4\EOHNCVkeHUh?=
SIMA M16zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwM{S1PFEh|ryP MkTDV2FPT0WU
MDA-MB-134-VI M1HwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjab45KSzVyPUCuN|Y6OjhizszN MY\TRW5ITVJ?
NCI-H1694 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkTWM2OD1yLkO3JO69VQ>? M1jNbnNCVkeHUh?=
EHEB NYHHSmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nicmlEPTB;MD6zPVA5PSEQvF2= NH\yblVUSU6JRWK=
U-266 NVOwV2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwM{m4OFYh|ryP NWfuOnVQW0GQR1XS
LC-1F NFHJfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS3TWM2OD1yLkSzO|Y2KM7:TR?= MUHTRW5ITVJ?
SHP-77 NU\acYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNEe4OVUh|ryP NYfkfXY1W0GQR1XS
LS-513 M4npOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGOG1KSzVyPUCuOFk{ODdizszN M3zvVXNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
5% DMSO+5% Tween 80+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
2.5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 問題2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID